Article Text

Download PDFPDF

Journal club
Innovative new diagnostic test to detect TB and rifampin resistance
  1. Narendra Babu Chinnappa
  1. Correspondence to Dr Narendra Babu Chinnappa, SpR, University Hospital Llandough, 74 Pan-Ty-Celyn road, Llandough, Cardiff CF64 2PH, UK; rcnaren{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Tuberculosis remains a major public health concern. Existing diagnostic tools are slow and result in delays initiating appropriate treatment. This is particularly a problem in patients with HIV, in whom sputum–smear analysis is frequently negative and those with multi-drug resistant strains.

In this study, the performance of an automated molecular assay for Mycobacterium tuberculosis (MTB) and resistance to rifampin (RIF) (Xpert MTB/RIF) was assessed. This test, through detection of an MTB-specific sequence of the rpoB gene and probing for rifampin-resistance determining region mutations, provides results within 2 h.

Three sputum samples were analysed from 1730 eligible patients with suspected tuberculosis in reference laboratories in Peru, Azerbaijan, South Africa and India. With a single test, 98.2% of patients with smear-positive, culture-positive tuberculosis were identified. Among those with smear-negative, culture-positive disease, the sensitivity of the assay was 72.5% with one test, 85.1% for two tests and 90.2% for three tests. The diagnostic specificity for tuberculosis was 99.2%. MTB/RIF testing correctly identified 97.6% of bacteria which had exhibited rifampin-resistance on phenotypic drug-susceptibility screening.

The MTB/RIF assay provides a prompt sensitive method of detection of tuberculosis and its potential resistance to rifampin. The benefit of a point-of-contact diagnostic test, with low man-power implications, sounds attractive for poorly funded healthcare systems. However, the authors admit several limitations to its uptake including high initial costs, rifampin-resistance testing only and a need to demonstrate similar efficacy in other healthcare settings.

Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010;363:1005–15.

View Abstract